object
evalu
effect
nasal
solut
compar
nasal
salin
solut
common
cold
symptom
mean
valid
measur
scale
carif
score
b
rhinoviru
infect
express
nasal
swab
c
frequenc
relaps
day
followup
method
infant
respiratori
infect
symptom
randomli
assign
receiv
either
nasal
solut
nasal
salin
solut
patient
evalu
carif
score
enrol
h
day
physician
parent
nasal
swab
obtain
enrol
h
one
week
result
carif
score
improv
group
episod
sneez
cough
fewer
studi
group
day
followup
p
signific
differ
found
nasopharyng
swab
rhinoviru
detect
cytokin
express
h
day
relaps
express
significantli
higher
rhinoviru
infect
children
studi
group
advers
effect
occur
conclus
data
suggest
solut
contain
resveratrol
plu
might
posit
impact
clinic
socioeconom
burden
due
infant
common
cold
common
cold
acut
viral
diseas
affect
upper
airway
caus
inflamm
nasal
pharyng
mucosa
frequent
human
diseas
signific
impact
public
health
qualiti
life
common
cold
usual
caus
mild
symptom
may
sever
infant
human
rhinovirus
hrv
preval
caus
common
cold
adult
children
total
virus
identifi
caus
common
cold
flulik
symptom
nineti
hrva
hrvb
serotyp
bind
glycoprotein
respiratori
epitheli
cell
remain
virus
bind
member
ldlr
famili
interact
hrv
epitheli
receptor
induc
secret
cytokin
chemokin
growth
factor
gmcsf
rant
type
iinterferon
induc
also
known
respons
recruit
lymphocyt
cell
type
airway
mucosa
respons
rhinoviru
infect
associ
increas
viru
titr
symptomat
cold
cytokin
chemokin
necessari
recruit
inflammatori
cell
well
host
antivir
respons
frequent
symptom
common
cold
rhinorrhoea
nasal
congest
sneez
sorescratchi
throat
chest
congest
follow
cough
headach
fever
usual
common
cold
selflimit
last
around
day
children
common
bacteri
complic
acut
otiti
media
complic
sinus
bronchiol
pneumonia
exacerb
asthma
treatment
common
cold
symptomat
base
antihistamin
antituss
decongest
drug
recommend
children
especi
year
age
howev
option
treat
even
children
overthecount
cough
cold
medic
recent
evalu
pharmacovigil
risk
assess
committe
prac
conclud
age
restrict
need
consid
ambroxol
bromhexin
furthermor
nasal
decongest
specif
design
babi
low
concentr
meter
dropper
devic
resveratrol
trihydroxystilben
polyphenol
occur
phytoalexin
differ
plant
speci
show
benefici
effect
inflammatori
condit
oncolog
cardiovascular
diseas
obes
type
diabet
neurodegen
diseas
resveratrol
modul
inflammatori
respons
inhibit
transcript
activ
nfkb
reduc
secret
rant
hrvinfect
nasal
epithelia
either
alon
combin
reduct
cytokin
product
correl
inhibit
hrv
replic
resveratrolinduc
resveratrol
low
solubl
low
bioavail
becom
unstabl
due
selfoxid
photosensit
combin
resveratrol
modifi
cmglucan
aqueou
solut
improv
stabil
without
modifi
biolog
properti
polysaccharid
abl
stimul
immun
system
nasal
spray
contain
resveratrol
cmglucan
reduc
nasal
symptom
respiratori
complic
children
allerg
rhiniti
also
reduc
use
antihistamin
solut
also
effect
reduc
nasal
symptom
children
upper
respiratori
tract
infect
preliminari
studi
show
prevent
effect
aerosol
formul
contain
resveratrolcmglucan
combin
children
recurr
respiratori
infect
time
data
regard
util
resveratrolcmglucan
combin
children
month
age
princip
aim
studi
verifi
effect
solut
compar
salin
solut
common
cold
symptom
treatment
infant
secondari
outcom
evalu
rhinoviru
infect
express
nasal
swab
cytokin
frequenc
relaps
day
followup
studi
popul
doubleblind
random
placebocontrol
clinic
trial
clinicaltrialsgov
perform
assess
efficaci
nasal
solut
common
cold
symptom
consecut
infant
month
admit
sign
symptom
suggest
acut
respiratori
ill
outpati
servic
neonatolog
unit
depart
biomed
human
oncolog
scienc
univers
bari
bari
itali
decemb
march
enrol
presenc
one
nasal
symptom
rhinorrhoea
b
nasal
congest
c
sneez
consid
inclus
criteria
exclus
criteria
preterm
infant
diagnosi
bronchopulmonari
dysplasia
b
major
acut
chronic
diseas
c
respiratori
malform
histori
asthma
allerg
rhiniti
autoimmun
diseas
allergi
particip
clinic
trial
e
use
respiratori
symptomat
treatment
studi
protocol
inform
consent
obtain
enrol
accord
local
ethic
committe
univers
bari
policlinico
hospit
bari
medic
school
bari
itali
approv
studi
protocol
infant
random
receiv
either
nasal
resveratrol
solut
placebo
drop
nostril
time
day
seven
day
random
perform
use
computergener
alloc
sequenc
nqueri
advisor
softwar
statist
solut
ltd
cork
ireland
avoid
disproportion
number
patient
group
random
scheme
perform
block
four
particip
particip
well
scientif
medic
personnel
dedic
studi
distribut
studi
agent
assess
sampl
analys
blind
group
assign
random
code
secur
data
analyz
nasal
solut
produc
noo
rome
itali
current
sold
itali
class
ec
medic
devic
brand
plu
isoton
solut
drop
contain
resveratrol
extract
polygonum
cuspidatum
placebo
compos
isoton
salin
solut
ident
visual
sensori
properti
order
maintain
doubleblind
statu
infant
characterist
collect
baselin
patient
underw
clinic
evalu
enrol
h
day
parent
ask
notifi
research
team
relaps
common
cold
day
enrol
data
record
standard
informat
form
common
cold
symptom
evalu
parent
mean
valid
scale
childhood
respiratori
infect
call
canadian
acut
respiratori
ill
flu
scale
carif
visit
carif
score
consist
item
answer
scale
problem
minor
problem
moder
problem
major
problem
carif
item
headach
sorethroat
muscl
ach
pain
applic
infant
henc
use
item
mean
point
applic
item
consid
measur
child
overal
ill
level
visit
independ
assess
child
overal
ill
level
complet
physician
meb
accord
anamnesi
clinic
evalu
presenc
sever
sign
symptom
associ
clinic
cold
record
ie
mucopurul
rhinorrhoea
nasal
congest
snore
sneez
product
nonproduct
cough
fever
night
wake
infantil
colic
lack
appetit
sign
symptom
rate
clinician
assign
numer
score
symptom
mild
symptom
moder
sever
score
individu
signssymptom
sum
creat
mean
total
medic
symptom
score
subset
analysi
also
consid
investig
differ
sign
symptom
nasal
sampl
obtain
patient
enrol
h
day
nasal
swab
midturbin
flpediat
copan
italia
brescia
itali
insert
approxim
onehalf
distanc
nare
bridg
nose
collect
ml
medium
copan
italia
optim
molecular
applic
sampl
store
c
analys
specimen
sent
frozen
viru
cytokinechemokin
analys
laboratori
microbiolog
sapienza
univers
rome
upon
receipt
aliquot
prepar
store
c
viral
rna
extract
realtim
rtpcr
viral
rna
extract
nasal
sampl
clinic
sampl
use
viru
spin
kit
qiagen
extract
rna
test
hrv
respiratori
synciti
viru
rsv
human
metapneumoviru
hmpv
onestep
rtpcr
assay
rhino
evcc
rsvhmpv
respect
biom
erieux
accord
manufactur
instruct
sampl
test
duplic
cellular
control
includ
assess
qualiti
sampl
collect
valid
presenc
cell
absenc
inhibitor
realtim
pcr
reaction
perform
abi
thermocycl
appli
biosystem
total
rna
extract
clinic
sampl
mini
rneasi
plu
kit
qiagen
hilden
germani
accord
manufactur
instruct
extract
rna
elut
rnasefre
water
revers
transcrib
cdna
iv
master
mix
invitrogen
cdna
test
gene
express
custom
taqman
array
thermofish
scientif
plate
contain
taqman
probe
specif
pcr
primer
set
run
abi
thermocycl
appli
biosystem
quantit
realtim
pcr
result
normal
rrna
express
housekeep
gene
fold
chang
gene
express
express
noninfect
group
chosen
control
comparison
group
baselin
made
tstudent
chisquar
test
numer
categor
variabl
respect
necessari
yate
correct
chisquar
test
use
evalu
trend
symptom
score
among
observ
time
relat
group
twoway
analysi
varianc
repeat
measur
perform
gene
express
data
non
infect
hrv
infect
subject
baselin
compar
use
unpair
ttest
mann
whitney
test
depend
result
normal
test
kolmogovsmirnov
test
pair
ttest
wilcoxon
test
use
test
group
follow
statist
analys
perform
use
spss
statist
version
ibm
corpor
armonk
ny
usa
graphpad
prism
version
graphpad
softwar
san
diego
ca
usa
infant
enrol
complet
entir
day
followup
enter
final
analysi
demograph
data
infant
shown
tabl
enrol
sampl
posit
hrv
one
hmpv
none
rsv
signif
differ
two
group
accord
demograph
data
posit
hrv
hmpv
rsv
baselin
report
carif
medic
mean
score
enrol
followup
group
shown
figur
carif
score
baselin
show
signific
differ
two
group
p
begin
treatment
record
signific
reduct
carif
score
group
signific
differ
group
time
effect
f
p
treatment
effect
f
p
interact
effect
f
p
time
point
signific
reduct
found
throughout
studi
period
f
p
vs
f
p
medic
assess
baselin
show
signific
differ
two
group
p
begin
treatment
record
signific
improv
symptom
group
without
signific
differ
group
time
effect
f
p
treatment
effect
f
p
interact
effect
f
p
time
point
signific
reduct
found
throughout
studi
period
f
p
vs
f
p
score
reduct
less
placebo
group
plu
group
interact
effect
f
p
symptom
analyz
individu
episod
sneez
product
nonproduct
cough
differ
plu
group
compar
placebo
group
figur
episod
sneez
show
differ
trend
two
group
interact
effect
f
p
plu
group
signific
increas
sneez
first
h
follow
f
p
follow
slight
signific
reduct
one
week
placebo
group
slight
increas
sneez
episod
even
signific
occur
first
h
f
p
follow
signific
increas
sneez
day
followup
f
p
differ
two
group
highli
signific
day
followup
p
regard
episod
product
nonproduct
cough
within
symptom
increas
significantli
placebo
group
f
p
decreas
significantli
plu
group
f
p
interact
effect
f
p
differ
two
group
highli
signific
day
followup
p
notabl
hrv
infect
infant
episod
cough
significantli
lower
plu
group
comparison
placebo
group
day
treatment
p
differ
detect
regard
mucopurul
rhinorrhoea
nasal
congest
snore
fever
night
wake
infantil
colic
lack
appetit
followup
data
shown
h
hrv
disappear
plu
children
placebo
group
children
p
hrv
neg
sampl
day
followup
greater
plu
group
compar
placebo
group
without
signific
vs
result
immunolog
marker
analysi
shown
tabl
highli
variabl
cytokin
express
level
detect
group
without
statist
signific
differ
studi
group
neither
enrol
h
treatment
sinc
infect
hrv
influenc
express
sever
cytokin
data
obtain
also
analyz
group
base
presenceabs
viral
infect
result
mrna
express
analysi
figur
reveal
level
significantli
upregul
hrv
infect
children
baselin
particular
show
increas
express
respons
hrv
infect
p
although
signific
also
found
increas
mrna
level
hrv
infect
compar
hrv
uninfect
children
baselin
h
followup
gene
express
hrv
infect
children
treat
plu
significantli
increas
compar
hrv
infect
subject
placebo
group
p
relaps
found
lower
plu
group
although
without
signific
differ
two
group
vs
p
advers
effect
record
resveratrol
extens
studi
abil
inhibit
growth
bacteria
fungi
virus
particular
preclin
studi
demonstr
resveratrol
abl
inhibit
replic
sever
respiratori
virus
rhinoviru
influenza
viru
respiratori
syncyti
viru
merscov
middl
east
respiratori
syndrom
coronaviru
human
metapneumoviru
reduc
virusinduc
inflammatori
mediat
low
bioavail
resveratrol
oral
administr
studi
evalu
therapeut
applic
resveratrol
infecti
diseas
topic
applic
resveratrol
mice
abl
reduc
skin
lesion
vagin
replic
due
herp
simplex
infect
knowledg
first
human
trial
effect
topic
applic
resveratrol
respiratori
infect
relat
symptom
despit
overal
non
superior
novel
approach
present
studi
show
intranas
instil
drop
contain
resveratrol
plu
may
provid
benefici
effect
infant
common
cold
notabl
find
respect
signific
reduct
sneez
product
nonproduct
cough
episod
find
keep
previou
result
show
capac
resveratrol
cmglucan
decreas
nasal
symptom
respiratori
complic
children
allerg
rhiniti
acut
rhinopharyng
despit
sampl
test
major
virus
caus
respiratori
infect
newborn
sampl
show
presenc
virus
ie
treat
group
placebo
group
sampl
except
one
presenc
hrv
identifi
noteworthi
hrv
infect
infant
episod
cough
significantli
lower
plu
group
comparison
placebo
group
day
treatment
moreov
mrna
level
hrv
infect
children
treat
plu
significantli
increas
compar
hrv
infect
subject
placebo
group
h
followup
sinc
demonstr
involv
type
ifn
antivir
respons
upon
bind
viral
antigen
pattern
recognit
receptor
result
suggest
plu
could
promot
antivir
defens
mainli
upregul
posit
effect
observ
plu
group
might
relat
antiinflammatori
antivir
mechan
resveratrol
immunemodul
osmot
activ
provid
glucan
accord
result
solut
contain
resveratrol
plu
may
interest
option
treatment
infant
common
cold
reduc
respiratori
symptom
decreas
relaps
sinc
limit
avail
symptomat
treatment
viral
infect
age
group
thu
result
suggest
resveratrol
plu
might
clinic
socioeconom
posit
impact
common
cold
benefici
effect
warrant
larg
scale
clinic
trial
assess
limit
studi
rel
low
number
viru
infect
sampl
b
possibl
differ
durat
viral
infect
time
enrol
influenc
tempor
evolut
infect
c
absenc
diagnosi
bacteri
infect
despit
promis
result
obtain
studi
evidencebas
studi
larger
cohort
need
assess
therapeut
potenti
solut
contain
resveratrol
plu
applic
clinic
set
author
contribut
statement
baldassarr
conceiv
design
experi
analyz
interpret
data
wrote
paper
p
mastromarino
e
schiavi
conceiv
design
experi
perform
experi
contribut
reagent
materi
analysi
tool
data
g
labellart
mc
pignatelli
contribut
reagent
materi
analysi
tool
data
fanelli
analyz
interpret
data
n
laforgia
di
mauro
capozza
r
panza
analyz
interpret
data
wrote
paper
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
